Compare · NBP vs NVO
NBP vs NVO
Side-by-side comparison of NovaBridge Biosciences (NBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 928.7x NBP ($201.9M).
- NVO has been more active in the news (11 items in the past 4 weeks vs 4 for NBP).
- NVO has more recent analyst coverage (25 ratings vs 1 for NBP).
- Company
- NovaBridge Biosciences
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $201.9M
- $187.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 11
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NBP
- SVP, Clinical Development Xu Cong Claire converted options into 9,382 units of Ordinary Shares and sold $13,766 worth of Ordinary Shares (3,494 units at $3.94), increasing direct ownership by 2% to 290,154 units (SEC Form 4)
- NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
- Officer Cao Sean Wuxiong sold $42,584 worth of Ordinary Shares (21,399 units at $1.99), decreasing direct ownership by 38% to 35,073 units (SEC Form 4) to cover taxes
- NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
- Officer Hagler Mark Arnold bought $577,300 worth of Ordinary Shares (230,000 units at $2.51) (SEC Form 4)
- SEC Form 3 filed by new insider Hagler Mark Arnold
- SEC Form 6-K filed by NovaBridge Biosciences
- NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
- Amendment: SEC Form 3 filed by new insider Xu Cong Claire
- SEC Form 6-K filed by NovaBridge Biosciences
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates